Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.50 |
| ▸ | AR | P10275 | 7/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31595268 | 0.91 | CRBN (0.49) | CRBNARBTKDDB1CDK9 | |
| SCHEMBL23267883 | 0.91 | CRBN (0.49) | CRBNARBTKDDB1CDK9 | |
| SCHEMBL31595777 | 0.84 | CRBN (0.53) | CRBNARBTKPLK4ALK | |
| SCHEMBL23249931 | 0.83 | CRBN (0.38) | CRBNARDDB1EGFR | |
| SCHEMBL23249934 | 0.83 | CRBN (0.38) | CRBNARDDB1EGFR | |
| SCHEMBL31595578 | 0.83 | BCL6 (0.47) | CRBNARBTKDDB1ALK | |
| SCHEMBL23249988 | 0.82 | CRBN (0.37) | CRBNARBTKDDB1EGFR | |
| SCHEMBL31306538 | 0.77 | CRBN (0.58) | CRBNARBTKDDB1CDK9 | |
| SCHEMBL23249944 | 0.77 | BCL6 (0.39) | ALK | |
| SCHEMBL29874089 | 0.77 | BCL6 (0.39) | ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | CRBN 5/4885AR 3563/4885BTK 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.